CYTK

64.60

5.45% 3.34

시간 외 거래: 64.00 -0.60 -0.93%

Cytokinetics Inc (CYTK)

개요 뉴스 가격 이력 옵션 체인 Financials CYTK 왜 하락? 토론 예측 주식 분할

전일 마감가:

$61.26

열려 있는:

$61.09

하루 거래량:

2.44M

Relative Volume:

1.27

시가총액:

$7.90B

수익:

$18.47M

순이익/손실:

$-589.53M

주가수익비율:

-12.28

EPS:

-5.26

순현금흐름:

$-399.80M

1주 성능:

+5.26%

1개월 성능:

-1.63%

6개월 성능:

+86.38%

1년 성능:

+31.33%

1일 변동 폭

$61.02

$64.89

1주일 범위

$58.85

$64.89

52주 변동 폭

$29.31

$70.98

Cytokinetics Inc Stock (CYTK) Company Profile

명칭

Cytokinetics Inc

부문

Healthcare (1115)

산업

Biotechnology (625)

전화

(650) 624-3000

주소

350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA

직원

498

트위터

@Cytokinetics

다음 수익 날짜

2024-11-06

최신 SEC 제출 서류

CYTK's Discussions on Twitter

CYTK을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
CYTK Cytokinetics Inc	64.60	7.49B	18.47M	-589.53M	-399.80M	-5.26
VRTX Vertex Pharmaceuticals Inc	468.38	113.87B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	776.54	80.22B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	406.40	52.56B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	803.74	49.31B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	175.07	37.37B	447.02M	-1.18B	-906.14M	-6.1812

Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2025-12-18	업그레이드	Goldman	Neutral → Buy
2025-07-30	재개	Raymond James	Mkt Perform
2025-04-24	개시	Barclays	Overweight
2025-02-07	개시	Citigroup	Buy
2025-01-22	개시	Stifel	Buy
2024-11-08	개시	RBC Capital Mkts	Outperform
2024-08-13	다운그레이드	Goldman	Buy → Neutral
2024-01-24	다운그레이드	UBS	Buy → Neutral
2024-01-05	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2023-11-09	개시	Goldman	Buy
2023-11-07	개시	B. Riley Securities	Buy
2023-08-15	개시	SVB Securities	Outperform
2023-02-17	개시	BofA Securities	Neutral
2022-12-23	재확인	Needham	Buy
2022-12-20	개시	Truist	Buy
2022-10-11	개시	UBS	Buy
2022-01-28	개시	Goldman	Buy
2021-12-22	개시	Oppenheimer	Outperform
2021-12-10	개시	JP Morgan	Overweight
2021-10-07	개시	Jefferies	Buy
2021-03-12	개시	Wolfe Research	Outperform
2021-02-18	개시	Barclays	Overweight
2021-01-20	재확인	H.C. Wainwright	Buy
2020-10-29	개시	Goldman	Neutral
2020-07-10	개시	Raymond James	Strong Buy
2020-05-05	개시	Mizuho	Buy
2020-04-09	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2018-09-21	개시	Cantor Fitzgerald	Overweight
2018-09-10	재개	Morgan Stanley	Equal-Weight
2017-11-22	재확인	Morgan Stanley	Overweight
2017-11-22	다운그레이드	Needham	Strong Buy → Buy
2017-11-21	재확인	H.C. Wainwright	Buy
2017-07-31	개시	Morgan Stanley	Overweight
2017-03-08	개시	Rodman & Renshaw	Buy
2017-02-06	업그레이드	Needham	Buy → Strong Buy
2016-12-16	개시	Cantor Fitzgerald	Overweight
2016-07-28	재확인	Needham	Buy
2015-11-10	재확인	FBR Capital	Outperform
2015-11-09	재확인	ROTH Capital	Buy
2015-07-24	재확인	MLV & Co	Buy
2014-12-31	재확인	ROTH Capital	Buy
2014-11-04	업그레이드	MLV & Co	Hold → Buy
2014-04-28	재확인	Needham	Buy

모두보기

Cytokinetics Inc 주식(CYTK)의 최신 뉴스

Jan 05, 2026

Insider Sell: Andrew Callos Sells 15,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus

Jan 05, 2026

Cytokinetics (NASDAQ:CYTK) EVP Sells $904,200.00 in Stock - MarketBeat

Jan 05, 2026

Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times

Jan 05, 2026

Tango Therapeutics Appoints Sung Lee to Board of Directors - GlobeNewswire Inc.

Jan 05, 2026

Jan 02, 2026

Cytokinetics (NASDAQ:CYTK) EVP Sells $112,590.76 in Stock - MarketBeat

Jan 02, 2026

Callos, Cytokinetics EVP, sells $112,584 in stock By Investing.com - Investing.com South Africa

Jan 02, 2026

Callos, Cytokinetics EVP, sells $112,584 in stock - Investing.com India

Jan 02, 2026

Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, ... - Bluefield Daily Telegraph

Jan 02, 2026

Notice to Long-Term Shareholders of Cytokinetics, Inc. - GlobeNewswire

Jan 02, 2026

Jan 01, 2026

Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed - ts2.tech

Jan 01, 2026

Cytokinetics, Incorporated (CYTK) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire

Jan 01, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Jan 01, 2026

Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next - ts2.tech

Jan 01, 2026

Moody Aldrich Partners LLC Buys Shares of 82,460 Cytokinetics, Incorporated $CYTK - MarketBeat

Jan 01, 2026

Dec 31, 2025

Cytokinetics Stock Soars: What’s Next? - StocksToTrade

Dec 31, 2025

Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing - ts2.tech

Dec 31, 2025

Cytokinetics (NASDAQ:CYTK) Trading 3% HigherStill a Buy? - MarketBeat

Dec 31, 2025

The Year-End 2025 Biotech Rally And What It Means For 2026 - Benzinga

Dec 31, 2025

Dec 30, 2025

Top Cytokinetics Insider Just Cashed Out in a High-Profile Stock Move - TipRanks

Dec 30, 2025

Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CY - GuruFocus

Dec 30, 2025

Cytokinetics (NASDAQ:CYTK) EVP Andrew Callos Sells 1,809 Shares of Stock - MarketBeat

Dec 30, 2025

Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. ... - Bluefield Daily Telegraph

Dec 30, 2025

Dec 29, 2025

Notice to Long-Term Shareholders of Alexandria Real Estate - GlobeNewswire

Dec 29, 2025

Dec 28, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

Dec 28, 2025

Dec 25, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Connect - ACCESS Newswire

Dec 25, 2025

Dec 24, 2025

Squarepoint Ops LLC Has $608,000 Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat

Dec 24, 2025

Analysts Have Conflicting Sentiments on These Healthcare Companies: Viridian Therapeutics (VRDN), Fortrea Holdings Inc. (FTRE) and Cytokinetics (CYTK) - The Globe and Mail

Dec 24, 2025

Dec 23, 2025

Insider Sell: Wendell Wierenga Sells 20,000 Shares of Cytokineti - GuruFocus

Dec 23, 2025

Cytokinetics (NASDAQ:CYTK) Director Sells $1,322,800.00 in Stock - MarketBeat

Dec 23, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Dec 23, 2025

Cytokinetics Insider Sold Shares Worth $1,322,800, According to a Recent SEC Filing - marketscreener.com

Dec 23, 2025

Morgan Stanley Maintains Overweight Rating on CYTK, Raises PT to $71 | CYTK Stock News - GuruFocus

Dec 23, 2025

Dec 22, 2025

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Moderna (MRNA) and Disc Medicine (IRON) - The Globe and Mail

Dec 22, 2025

Citizens Maintains Cytokinetics (CYTK) Market Outperform Recommendation - Nasdaq

Dec 22, 2025

RBC Capital Maintains Cytokinetics (CYTK) Outperform Recommendation - Nasdaq

Dec 22, 2025

Cytokinetics: Small Label Differences With Big Commercial Stakes (CYTK) - Seeking Alpha

Dec 22, 2025

Cytokinetics Earnings Boost After FDA Approval - StocksToTrade

Dec 22, 2025

Cytokinetics’ Breakthrough: Stock Set for Big Gains? - StocksToTrade

Dec 22, 2025

FDA Approval Puts New Cytokinetics Heart Drug in Competition With Fast-Growing BMS Med - MedCity News

Dec 22, 2025

Cytokinetics (CYTK) Stock Hits 52-Week High as FDA Approval of Myqorzo Triggers Analyst Price-Target Hikes - ts2.tech

Dec 22, 2025

FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM - BioWorld MedTech

Dec 22, 2025

Investors Buy Large Volume of Cytokinetics Call Options (NASDAQ:CYTK) - MarketBeat

Dec 22, 2025

Cytokinetics jumps after FDA approves its drug for rare heart disease - TradingView — Track All Markets

Dec 22, 2025

Cytokinetics Surges as FDA Grants Approval for Myqorzo - timothysykes.com

Dec 22, 2025

Why Is Cytokinetics Stock Soaring Monday?Cytokinetics (NASDAQ:CYTK) - Benzinga

Dec 22, 2025

Cytokinetics Wins FDA Approval for Cardiovascular Drug, Stock up - Finviz

Dec 22, 2025

UniFirst, Adeia, Cytokinetics And Other Big Stocks Moving Higher On Monday - Benzinga

Dec 22, 2025

Cytokinetics stock hits 52-week high at 69.46 USD - Investing.com

Dec 22, 2025